{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:28:37Z","timestamp":1788366517355,"version":"build-2803163510"},"reference-count":102,"publisher":"Informa UK Limited","issue":"20","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2024,6,23]]},"DOI":"10.1080\/14796694.2024.2340959","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T10:48:29Z","timestamp":1725446909000},"page":"1435-1450","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Treatment options for biliary tract cancer: unmet needs, new targets and opportunities from both physicians' and patients' perspectives"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0066-2672","authenticated-orcid":false,"given":"Rachna T","family":"Shroff","sequence":"first","affiliation":[{"name":"University of Arizona Cancer Center, University of Arizona, Tucson,\u00a0AZ 85719,\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Bachini","sequence":"additional","affiliation":[{"name":"Cholangiocarcinoma Foundation, 5526 West 13400 South, #510,\u00a0Herriman, UT\u00a0USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10286-z"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082039"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02576"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29020050"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.506"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"e_1_3_7_9_1","unstructured":"FDA approves pembrolizumab with chemotherapy for biliary tract cancer [Internet]. U.S. Food and Drug Administration. 2023 Oct 31 [cited 2023 Nov 22]. Available from: www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-chemotherapy-biliary-tract-cancer"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.09.150"},{"issue":"1","key":"e_1_3_7_11_1","first-page":"82","article-title":"The importance of molecular testing in the treatment of cholangiocarcinoma","volume":"8","author":"Malka D","year":"2020","unstructured":"Malka D, Siebenh\u00fcner AR, Mertens JC, et al. The importance of molecular testing in the treatment of cholangiocarcinoma. EMJ Oncol. 2020;8(1):82\u201394.","journal-title":"EMJ Oncol."},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00027-9"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0138-2"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2021.2485"},{"key":"e_1_3_7_15_1","unstructured":"FDA approves durvalumab for locally advanced or metastatic biliary tract cancer [Internet]. U.S. Food and Drug Administration. 2022 Sep 2 [cited 2023 Nov 22]. Available from: www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-locally-advanced-or-metastatic-biliary-tract-cancer"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.1219"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA490"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3212"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102170"},{"key":"e_1_3_7_21_1","unstructured":"FDA approves first targeted treatment for patients with cholangiocarcinoma a cancer of bile ducts [Internet]. U.S. Food and Drug Administration. 2020 Apr 17 [cited 2023 Nov 22]. Available from: www.fda.gov\/news-events\/press-announcements\/fda-approves-first-targeted-treatment-patients-cholangiocarcinoma-cancer-bile-ducts"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30109-1"},{"key":"e_1_3_7_23_1","unstructured":"FDA grants accelerated approval to futibatinib for cholangiocarcinoma [Internet]. U.S. Food and Drug Administration. 2022 Sep 30 [cited 2023 Nov 22]. Available from: www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-futibatinib-cholangiocarcinoma"},{"key":"e_1_3_7_24_1","unstructured":"Highlights of Prescribing Information LYTGOBI\u00ae (futibatinib) [Internet]. 2022 Sept [cited 2023 Nov 22]. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214801s000lbl.pdf"},{"key":"e_1_3_7_25_1","unstructured":"FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma [Internet]. U.S. Food and Drug Administration. 2021 May 28 [cited 2023 Nov 22]. Available from: www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma"},{"key":"e_1_3_7_26_1","unstructured":"Important information. Truseltiq\u00ae (Infigratinib) capsules. Notice of permanent discontinuation of distribution [Internet]. CCA News. 2022 Oct 11 [cited 2023 Nov 22]. Available from: www.ccanewsonline.com\/web-exclusives\/press-releases\/october-10-2022-truseltiq"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29100626"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0475"},{"key":"e_1_3_7_29_1","unstructured":"REFOCUS: a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in patients with ICC and other advanced solid tumors. ClinicalTrials.gov Identifier: NCT04526106 [Internet] U.S. National Library of Medicine. 2020 [cited 2023 Nov 22]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04526106"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4009"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30157-1"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1077"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810869"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21018"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.04.473"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0214"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00089"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100260"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00336-3"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0035"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112431"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004413"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4097"},{"key":"e_1_3_7_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00242-5"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00606"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.206"},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30321-1"},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.574"},{"key":"e_1_3_7_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1896703"},{"key":"e_1_3_7_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714448"},{"key":"e_1_3_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6"},{"key":"e_1_3_7_55_1","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2016.10.04"},{"key":"e_1_3_7_56_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S304281"},{"key":"e_1_3_7_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.519"},{"key":"e_1_3_7_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.9"},{"key":"e_1_3_7_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103695"},{"key":"e_1_3_7_60_1","doi-asserted-by":"publisher","DOI":"10.46883\/2022.25920971"},{"key":"e_1_3_7_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-021-00368-w"},{"key":"e_1_3_7_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01931-y"},{"key":"e_1_3_7_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00571-8"},{"issue":"12","key":"e_1_3_7_64_1","first-page":"5762","article-title":"Therapeutic opportunities in cancer therapy: targeting the p53-MDM2\/MDMX interactions","volume":"11","author":"Munisamy M","year":"2021","unstructured":"Munisamy M, Mukherjee N, Thomas L, et al. Therapeutic opportunities in cancer therapy: targeting the p53-MDM2\/MDMX interactions. Am J Cancer Res. 2021;11(12):5762\u20135781.","journal-title":"Am J Cancer Res."},{"key":"e_1_3_7_65_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01169-0"},{"key":"e_1_3_7_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2017.180"},{"key":"e_1_3_7_67_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom10111474"},{"key":"e_1_3_7_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2010.01.009"},{"key":"e_1_3_7_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/362857a0"},{"key":"e_1_3_7_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3375"},{"key":"e_1_3_7_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.531"},{"key":"e_1_3_7_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153116"},{"key":"e_1_3_7_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.11.030"},{"key":"e_1_3_7_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31951"},{"key":"e_1_3_7_75_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001006"},{"key":"e_1_3_7_76_1","doi-asserted-by":"publisher","DOI":"10.1177\/1176935120922154"},{"key":"e_1_3_7_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004280000201"},{"issue":"10","key":"e_1_3_7_78_1","first-page":"3961","article-title":"Expression of CD44 and MDM2 in cholangiocarcinoma is correlated with poor clinicopathologic characteristics","volume":"12","author":"Wattanawongdon W","year":"2019","unstructured":"Wattanawongdon W, Simawaranon Bartpho T, Tongtawee T. Expression of CD44 and MDM2 in cholangiocarcinoma is correlated with poor clinicopathologic characteristics. Int J Clin Exp Pathol. 2019;12(10):3961\u20133967.","journal-title":"Int J Clin Exp Pathol."},{"key":"e_1_3_7_79_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0078"},{"key":"e_1_3_7_80_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0715"},{"key":"e_1_3_7_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0949-z"},{"key":"e_1_3_7_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-021-01141-2"},{"key":"e_1_3_7_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00840-1"},{"key":"e_1_3_7_84_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1295"},{"key":"e_1_3_7_85_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0750-6"},{"key":"e_1_3_7_86_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9517"},{"key":"e_1_3_7_87_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1291"},{"key":"e_1_3_7_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01285"},{"key":"e_1_3_7_89_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14875"},{"key":"e_1_3_7_90_1","unstructured":"Rain therapeutics provides interim analysis of Phase II basket trial of Milademetan for MDM2-amplified advanced solid tumors (MANTRA-2) [Internet]. Rain Therapeutics. 2022 Nov 4 [cited 2023 Nov 22]. Available from: www.rainoncology.com\/news-press-releases\/rain-therapeutics-provides-interim-analysis-of-phase-2-basket-trial-of-milademetan-for-mdm2-amplified-advanced-solid-tumors-mantra-2"},{"key":"e_1_3_7_91_1","unstructured":"Milademetan shows early activity in MDM2-amplified advanced solid tumors [Internet]. OncLive\u00a9. 2022 Nov 10 [cited 2023 Nov 22]. Available from: www.onclive.com\/view\/milademetan-shows-early-activity-in-mdm2-amplified-advanced-solid-tumors"},{"key":"e_1_3_7_92_1","unstructured":"Press release Rain Oncology announces topline results from Phase III MANTRA trial of milademetan for the treatment of dedifferentiated liposarcoma [Internet]. Rain Oncology. 2023 May 22 [cited 2023 Nov 22]. Available from: www.rainoncology.com\/news-press-releases\/rain-oncology-announces-topline-results-from-phase-3-mantra-trial-of-milademetan-for-the-treatment-of-dedifferentiated-liposarcoma"},{"key":"e_1_3_7_93_1","unstructured":"Press release Rain Oncology provides company update and outlines strategic priorities of milademetan clinical programs [Internet]. Rain Oncology. 2023 May 30 [cited 2023 Nov 22]. Available from: www.rainoncology.com\/news-press-releases\/rain-oncology-provides-company-update-and-outlines-strategic-priorities-of-milademetan-clinical-programs"},{"key":"e_1_3_7_94_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02158-z"},{"key":"e_1_3_7_95_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-4866"},{"key":"e_1_3_7_96_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.3004"},{"key":"e_1_3_7_97_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.3095"},{"key":"e_1_3_7_98_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.3016"},{"key":"e_1_3_7_99_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0153"},{"key":"e_1_3_7_100_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S440979"},{"key":"e_1_3_7_101_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0963"},{"key":"e_1_3_7_102_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0963"},{"key":"e_1_3_7_103_1","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2021.1609879"},{"key":"e_1_3_7_104_1","unstructured":"Biomarkers Matter [Internet]. Cholangiocarcinoma Foundation. 2022 [cited 2023 Nov 22]. Available from: https:\/\/cholangiocarcinoma.org\/mutationsmatter\/biomarkers-matter\/"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2024.2340959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T15:28:01Z","timestamp":1727278081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2024.2340959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":102,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2024,6,23]]}},"alternative-id":["10.1080\/14796694.2024.2340959"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2024.2340959","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-12-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}